The overall objective is to determine the molecular basis for selective antitumor activity of the dimeric Catharanthus alkaloids, vincristine (VCR) and vinblastine (VLB). Experiments will be designed to elucidate the biochemical basis for selective retention of VCR in human rhabdomyosarcomas (RMS) sensitive in vivo, but not in resistant lines, or host (mouse) limiting tissues. Cytosols will be prepared from RMS growing as xenografts in mice. The pool of unpolymerized tubulin will be determined, as will the association constants for VLB and VCR using Scatchard analysis. Isoforms of Alpha and Beta-tubulin will be identified using gel electrophoresis and monoclonal antibodies. Similar analyses will be carried out using normal tissues, where stable VCR-protein complexes are formed. Human RMS growing as xenografts, have been selected for resistance to VCR under clinically relevant conditions. One line (Rh18/VCR-3) characterized exhibits quantitative and qualitative changes in Beta-tubulin isoforms, and decreased retention of VCR. In order to determine whether these changes are a consequence of altered gene expression, mRNAs for Beta-tubulin will be isolated and characterized using 32p-cDNA homologous to Beta-tubulin mRNA. Beta-Tubulin will be hybridized to cDNA bound to filters, eluted and translated in vitro. Translation products from parent and resistant lines will be compared to soluble forms of Beta-tubulins present in these tumors. Rh12/VCR, also selected for resistance in vivo, will be characterized with respect to VCR retention, the expression of tubulins and compared to its parent line, which is exquisitely sensitive to VCR. In cytosols prepared from mouse intestine, liver, spleen and kidney, failure to retain VCR may be due to proteolytic cleavage of tubulin dimer, causing release of the ligand. This 'protease' activity will be characterized with respect to substrate specificity (using 125I-iodinated tubulin, -intermediate filaments and -neurofilaments), Ca++ dependence, pH optimum, and tissue distribution. Its relevance to the rapid efflux of VCR from tissues, and regulation of tubulin pools will be examined. Vinca alkaloids form the backbone of chemotherapy of childhood RMS, yet the cellular pharmacology, basis for selectivity, and mechanisms of cellular resistance are poorly understood. The RMS xenograft model is unique in allowing the study of changes associated with acquired resistance to VCR in human cancers, selected under controlled conditions in vivo. The phenotypes of such resistant lines may be of relevance to resistance in human cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA038933-01
Application #
3177422
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1985-01-01
Project End
1987-12-31
Budget Start
1985-01-01
Budget End
1985-12-31
Support Year
1
Fiscal Year
1985
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Strother, D R; Parham, D M; Houghton, P J (1990) Expression of the 5.1 H11 antigen, a fetal muscle surface antigen, in normal and neoplastic tissue. Arch Pathol Lab Med 114:593-6
Horton, J K; Thimmaiah, K N; Houghton, J A et al. (1989) Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 38:1727-36
Houghton, P J; Houghton, J A (1989) Xenografts of pediatric solid tumors: predictive intermediate models? Haematol Blood Transfus 32:149-55
Horton, J K; Houghton, P J; Houghton, J A (1988) Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol 37:3995-4000
Bowman, L C; Houghton, J A; Houghton, P J (1988) Formation and stability of vincristine-tubulin complex in kidney cytosols. Role of GTP and GTP hydrolysis. Biochem Pharmacol 37:1251-7
Horowitz, M E; Etcubanas, E; Christensen, M L et al. (1988) Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 6:308-14
Douglass, E C; Valentine, M; Etcubanas, E et al. (1987) A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 45:148-55
Houghton, P J; Houghton, J A; Bowman, L C et al. (1987) Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate? Anticancer Drug Des 2:165-79
Houghton, J A; Meyer, W H; Houghton, P J (1987) Scheduling of vincristine: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration. Cancer Treat Rep 71:717-21
Horton, J K; Houghton, P J; Houghton, J A (1987) Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard. Cancer Res 47:6288-93

Showing the most recent 10 out of 16 publications